{"groups":[{"description":"Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nOral palonosetron\n\nDexamethasone","id":"FG000","title":"Oral Palonosteron Plus Dexamethasone"},{"description":"Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nI.V. palonosetron\n\nDexamethasone","id":"FG001","title":"I.V. Palonosetron Plus Dexamethasone"}],"periods":[{"milestones":[{"achievements":[{"comment":"number of randomised patients","groupId":"FG000","numSubjects":"371"},{"comment":"number of randomised patients","groupId":"FG001","numSubjects":"372"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"359"},{"groupId":"FG001","numSubjects":"351"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"21"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 743 patients were randomized (ITT population), 739 received study medications (oral or I.V. palonosetron plus dexamethasone, safety population), 738 received study medications (oral or I.V. palonosetron plus dexamethasone, safety population) and chemotherapy (FAS population)"}